ITI Frequently Asked Questions
A. The International Trachoma Initiative, or ITI, is a program of the Task Force for Global Health in partnership with Pfizer, based in Decatur, Georgia.
ITI works in partnership with national governments and the Ministries of Health to coordinate the Pfizer Inc. donation of the antibiotic Zithromax® to treat and prevent trachoma.
A. The Task Force for Global Health is a not-for-profit, public health organization with a 27-year history of improving the lives of millions of people around the world. Working with a broad network of public and private sector partners, the Task Force manages an array of initiatives focused on neglected tropical diseases, immunization and vaccines, and health systems strengthening. For more information about the impact of the Task Force and its programs, visit www.taskforce.org.
A. ITI works primarily in Africa and Asia.
A. Since 1999, ITI has been engaged in 29 countries, and plans to be active in 42 countries by 2015.
A. ITI manages the donation of the antibiotic Zithromax®, donated by Pfizer Inc. The drug treats and prevents trachoma.
ITI also promotes the WHO-endorsed SAFE Strategy, which combines treatment (Surgery and Antibiotics) with prevention (Facial cleanliness and Environmental improvement).
Since 1999, Pfizer has donated more than 340 million treatments of Zithromax®.
A. The decision is made by the Trachoma Expert Committee (TEC), an independent decision-making body of seven experts that meets twice a year to review country applications for Zithromax®.
A. GET 2020 is the Alliance for Global Elimination of Blinding Trachoma by 2020. It is led by the World Health Organization (WHO).
Sign up for our Email Newsletter